165 related articles for article (PubMed ID: 28110902)
1. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
Jones EF; Ray KM; Li W; Seo Y; Franc BL; Chien AJ; Esserman LJ; Pampaloni MH; Joe BN; Hylton NM
Clin Breast Cancer; 2017 Jun; 17(3):e155-e159. PubMed ID: 28110902
[No Abstract] [Full Text] [Related]
2. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
3. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
4. 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study.
Jin S; Kim SB; Ahn JH; Jung KH; Ahn SH; Son BH; Lee JW; Gong G; Kim HO; Moon DH
J Surg Oncol; 2013 Feb; 107(2):180-7. PubMed ID: 22948739
[TBL] [Abstract][Full Text] [Related]
5. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer.
Jasra S; Opyrchal M; Norton L; Mehta R
Clin Breast Cancer; 2017 Feb; 17(1):e37-e41. PubMed ID: 27665021
[No Abstract] [Full Text] [Related]
6. Predicting pathological complete response in breast cancer early.
Groheux D
Lancet Oncol; 2014 Dec; 15(13):1415-1416. PubMed ID: 25456356
[No Abstract] [Full Text] [Related]
7. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer. Predicting nonresponders--light at the end of the PET tunnel.
Errico A
Nat Rev Clin Oncol; 2015 Jan; 12(1):2. PubMed ID: 25403940
[No Abstract] [Full Text] [Related]
10. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from an unusual case of inflammatory breast cancer.
Harrison AM; Zendejas B; Ali SM; Scow JS; Farley DR
J Surg Educ; 2012; 69(3):350-4. PubMed ID: 22483137
[TBL] [Abstract][Full Text] [Related]
12. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
13. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration.
Semple SI; Staff RT; Heys SD; Redpath TW; Welch AE; Ahearn TS; Hutcheon A; Gilbert FJ
Ann Oncol; 2006 Sep; 17(9):1393-8. PubMed ID: 16788001
[TBL] [Abstract][Full Text] [Related]
14. Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
Srour MK; Lee M; Walcott-Sapp S; Luu M; Chung A; Giuliano AE; Amersi F
Ann Surg Oncol; 2019 Oct; 26(10):3289-3294. PubMed ID: 31342365
[TBL] [Abstract][Full Text] [Related]
15. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK
Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
[TBL] [Abstract][Full Text] [Related]
19. PET Imaging of Breast Cancer: Role in Patient Management.
Lebron L; Greenspan D; Pandit-Taskar N
PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
[TBL] [Abstract][Full Text] [Related]
20. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]